InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers ...Middle East

PR Newswire - News
InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers
NANJING, China, May 8, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, today announced that it had completed $15 million in...

Hence then, the article about inxmed raised 15 million in series b financing to advance innovative therapies to drug resistant cancers was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers )

Apple Storegoogle play

Last updated :

Also on site :